StreetInsider.com News Articles

Valion Bio names CFO Lisa Wolf as president and COO after CEO exits

Tue, 01 Sep 2026 08:01:39 -0400

Valion Bio, Inc. (NASDAQ: VBIO), a clinical-stage biopharmaceutical company, has appointed Chief Financial Officer Lisa Wolf to the additional roles of President and Chief Operating Officer, effective immediately, following the departure of former Chief Executive Officer Michael K. Handley.

Wolf will retain her CFO responsibilities while assuming executive leadership of the company. According to a company statement, she will oversee the advancement of Valion's lead product candidate, Entolimod, and direct efforts to expand government, international, and commercial partnership opportunities.

"Lisa has earned the deep respect and confidence of the Board, and she is uniquely qualified to lead Valion through this next phase

Valion Bio Announces Changes to Management and Board of Directors

Tue, 01 Sep 2026 08:00:00 -0400

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.

Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation Syndrome ("ARS") market by 2032 and a multi-billion-dollar oncology supportive-care opportunity through its differentiated dual-tissue cytoprotection platform¹^˒²
Focused on Value Creation: Streamlined leadership and additional Board expertise are designed to accelerate execution, strengthen commercial opportunities and better align Valion's market valuation with the underlying value of its assets, capabilities, and future prospects

SAN ANTONIO, TX / ACCESS

Valion Bio Announces Changes to Management and Board of Directors

Tue, 01 Sep 2026 08:00:00 -0400

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.
Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation Syndrome ("ARS") market by 2032 and a multi-billion-dollar oncology supportive-care opportunity through its differentiated dual-tissue cytoprotection platform¹^˒²
Focused on Value Creation: Streamlined leadership and additional Board expertise are designed to accelerate execution, strengthen commercial opportunities and better align Valion's market valuation with the underlying value of its assets, capabilities, and future prospects

SAN ANTONIO, TX / ACCESS

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Thu, 27 Aug 2026 20:33:00 -0400
si-local-file:///var/storage/secattach/20260827/26991766.html

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Thu, 27 Aug 2026 20:33:00 -0400
si-local-file:///var/storage/secattach/20260827/26991766.html

Valion Bio sets 1-for-25 reverse split to meet Nasdaq rules

Thu, 27 Aug 2026 08:31:43 -0400

Valion Bio, Inc. (Nasdaq: VBIO) announced that its board of directors has declared a 1-for-25 reverse stock split of its issued and outstanding shares of common stock, effective August 31, 2026, at 12:01 a.m. Eastern Time.

The move is intended to bring the San Antonio-based company into compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. Stockholders approved the reverse stock split at a special meeting held August 14, 2026.

Trading on a split-adjusted basis is expected to begin when markets open on August 31, 2026, under the existing ticker symbol "VBIO." The new CUSIP number

Form 8-K Valion Bio, Inc. For: Aug 26

Thu, 27 Aug 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260827/26985454.html

Form 8-K Valion Bio, Inc. For: Aug 26

Thu, 27 Aug 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260827/26985454.html

Valion Bio Announces Reverse Stock Split

Thu, 27 Aug 2026 08:30:00 -0400

SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").
The reverse stock split was approved by the stockholders of the Company at a special meeting of the Company held

Valion Bio Announces Reverse Stock Split

Thu, 27 Aug 2026 08:30:00 -0400

SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").
The reverse stock split was approved by the stockholders of the Company at a special meeting of the Company held

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Mon, 24 Aug 2026 19:42:00 -0400
si-local-file:///var/storage/secattach/20260824/26969503.html

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Mon, 24 Aug 2026 19:42:00 -0400
si-local-file:///var/storage/secattach/20260824/26969503.html

Form RW Valion Bio, Inc.

Mon, 24 Aug 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260824/26963777.html

Form RW Valion Bio, Inc.

Mon, 24 Aug 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260824/26963777.html

Form 8-K/A Valion Bio, Inc. For: Aug 14

Thu, 20 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260820/26956369.html

Form 8-K/A Valion Bio, Inc. For: Aug 14

Thu, 20 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260820/26956369.html

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Wed, 19 Aug 2026 21:09:00 -0400
si-local-file:///var/storage/secattach/20260819/26951679.html

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Wed, 19 Aug 2026 21:09:00 -0400
si-local-file:///var/storage/secattach/20260819/26951679.html

Form 8-K Valion Bio, Inc. For: Aug 14

Mon, 17 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260817/26934348.html

Form 8-K Valion Bio, Inc. For: Aug 14

Mon, 17 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260817/26934348.html

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Fri, 14 Aug 2026 19:15:00 -0400
si-local-file:///var/storage/secattach/20260814/26933209.html

Form SCHEDULE 13D/A Valion Bio, Inc. Filed by: 3i, LP

Fri, 14 Aug 2026 19:15:00 -0400
si-local-file:///var/storage/secattach/20260814/26933209.html

Form 10-Q Valion Bio, Inc. For: Jun 30

Fri, 14 Aug 2026 17:31:00 -0400
si-local-file:///var/storage/secattach/20260814/26932948.html

Form 10-Q Valion Bio, Inc. For: Jun 30

Fri, 14 Aug 2026 17:31:00 -0400
si-local-file:///var/storage/secattach/20260814/26932948.html

Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Thu, 13 Aug 2026 10:00:00 -0400

Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement
Formal review accepted July 22 • Ministry begins technical assessment • Regulatory requirements defined • Potential decision as early as Q4 2026
Near-Term Regulatory Catalyst
Formal review underway: Ukraine's Ministry of Health accepted the Entolimod dossier for formal review on July 22, 2026.
Technical assessment underway: Ukraine's Ministry of Health has begun technical assessment of the dossier and issued its first round of questions, relating to the physicochemical characterization of the drug product that would be supplied under